Thus, compound 4n representsa novel pharmacological probe to investigate the involvement of variousadrenoceptors in relevant indications and, at the same time, a promisinglead candidate for further preclinical development to treat sepsis-inducedliver inflammation and other ADRA2A-mediated pathologies. Here, ADRA2A is linked to Sepsis.